Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309010 | 0.93 | KMT2A (0.58) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL309318 | 0.88 | HDAC3 (0.49) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14151374 | 0.86 | KMT2A (0.52) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14151561 | 0.86 | KMT2A (0.52) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL309319 | 0.84 | HDAC3 (0.52) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14494706 | 0.83 | HDAC3 (0.56) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL731546 | 0.83 | KMT2A (0.58) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL309037 | 0.83 | GPR119 (0.58) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5315647 | 0.82 | HDAC3 (0.55) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14149995 | 0.82 | KMT2A (0.52) | KMT2AHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111406-B1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK SHARP & DOHME (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8093389-B2 | e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases | MERCK SHARP & DOHME CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1910375-B1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7935712-B2 | Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-7410976-B2 | Spirochromanone derivatives | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080171761-A1 | Substituted spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-20070021453-A1 | Novel spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | KMT2A 3686/4885HDAC3 107/4885HDAC4 948/4885 |
| US-20070021453-A1 | Novel spirochromanone derivatives | HSD17B7, CYP11B2, CYP11B1 | KMT2A 3449/4885HDAC3 435/4885HDAC4 1422/4885 |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | ACACA, ACACB, ACAT1 | KMT2A 2873/4885HDAC3 354/4885HDAC4 905/4885 |
| US-20080171761-A1 | Substituted spirochromanone derivatives | CBR3, CBR1, CNKSR1 | KMT2A 3886/4885HDAC3 84/4885HDAC4 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.